본문 바로가기
KERD
논문KCI 등재

Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary

전덕인|정명훈|추일한|정종현|김문두|박원명|Jeong Seok Seo|Won Kim|Sung-Yong Park|Jung Goo Lee|Chan-Mo Yang|Bo-Hyun Yoon|Se-Hoon Shim|Young Sup Woo|Inki Sohn
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2022.11|Clinical Psychopharmacology and Neuroscience|제20권 제4호|pp. 747-761|DOI 10.9758/cpn.2022.20.4.747

1

조회

0

다운로드

4

인용

0

참고문헌

키워드

Bipolar disorderKMAP-BP 2022Expert consensusPharmacotherapy.

초록

Objective: We revised the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP), first published in 2002 and revised in 2006, 2010, 2014, and 2018, to reflect recent progress in the treatment of bipolar disorder. Methods: The questionnaires consisted of 56 items for adult patients and 7 items for child/adolescent patients, and were used to obtain the consensus of experts regarding pharmacological treatment strategies for various phases of bipolar disorder. The review committee included 87 Korean psychiatrists and 40 child and adolescent psychiatry experts. Results: For treatment of manic episodes, a combination of a mood stabilizer (MS) and atypical antipsychotics (AAP), or monotherapy with MS or AAP were recommended as first-line treatments. Combinations of MS and AAP, or AAP and lamotrigine (LMT) were recommended as first-line treatments for depressive episodes regardless of the severity. Monotherapy with MS, AAP, or LMT were also first-line treatments for mild to moderate depressive episodes. For mixed features, a combination of MS and AAP, or monotherapy with AAP or MS were recommended as first-line treatments, and a combination of AAP and LMT, or MS and LMT were the first-line treatments for depressive mixed state. Conclusion: The recommendations of the KMAP-BP 2022 have changed from the previous version, to reflect the evolution of the social culture and healthcare system in Korea and recent evidence regarding pharmacotherapy of bipolar disorder. The KMAP-BP 2022 provides clinicians with a wealth of information regarding appropriate strategies to treat patients with bipolar disorder.

Abstract

Objective: We revised the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP), first published in 2002 and revised in 2006, 2010, 2014, and 2018, to reflect recent progress in the treatment of bipolar disorder. Methods: The questionnaires consisted of 56 items for adult patients and 7 items for child/adolescent patients, and were used to obtain the consensus of experts regarding pharmacological treatment strategies for various phases of bipolar disorder. The review committee included 87 Korean psychiatrists and 40 child and adolescent psychiatry experts. Results: For treatment of manic episodes, a combination of a mood stabilizer (MS) and atypical antipsychotics (AAP), or monotherapy with MS or AAP were recommended as first-line treatments. Combinations of MS and AAP, or AAP and lamotrigine (LMT) were recommended as first-line treatments for depressive episodes regardless of the severity. Monotherapy with MS, AAP, or LMT were also first-line treatments for mild to moderate depressive episodes. For mixed features, a combination of MS and AAP, or monotherapy with AAP or MS were recommended as first-line treatments, and a combination of AAP and LMT, or MS and LMT were the first-line treatments for depressive mixed state. Conclusion: The recommendations of the KMAP-BP 2022 have changed from the previous version, to reflect the evolution of the social culture and healthcare system in Korea and recent evidence regarding pharmacotherapy of bipolar disorder. The KMAP-BP 2022 provides clinicians with a wealth of information regarding appropriate strategies to treat patients with bipolar disorder.

참고문헌 (37)

  1. Carvalho AF, "Bipolar disorder", N Engl J Med, 383, pp.58~66 (2020)
  2. Shih-Ku Lin, "Prescription Patterns for Bipolar Disorder in Asian Countries: Findings from Research on Asian Prescription Pattern-Bipolar Disorder", Clinical Psychopharmacology and Neuroscience, 20(1), pp.61~69 (2022), 대한정신약물학회[DOI]
  3. López-Muñoz F, "A history of the pharmacological treatment of bipolar disorder", Int J Mol Sci, 19, pp.2143~ (2018)
  4. Fornaro M, "The concept and management of acute episodes of treatment-resistant bipolar disorder : a systematic review and exploratory meta-analysis of randomized controlled trials", J Affect Disord, 276, pp.970~983 (2020)
  5. Fountoulakis KN, "The International College of Neuro-Psychopharmacology(CINP)treatment guidelines for bipolar disorder in adults(CINP-BD-2017), part 3 : the clinical guidelines", Int J Neuropsychopharmacol, 20, pp.180~195 (2017)
  6. Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders : acute and long-term treatment of mixed states in bipolar disorder", World J Biol Psychiatry, 19, pp.2~58 (2018)
  7. Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)2018 guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
  8. Malhi GS, "The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders : bipolar disorder summary", Bipolar Disord, 22, pp.805~821 (2020)
  9. Jung Suk Lee, "Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms", Clinical Psychopharmacology and Neuroscience, 18(3), pp.386~394 (2020), 대한정신약물학회[DOI]
  10. Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary", Clinical Psychopharmacology and Neuroscience, 19(4), pp.751~772 (2021), 대한정신약물학회[DOI]
  11. 박원명, "양극성 장애의 한국형 약물치료 알고리듬", 대한정신약물학회지, 13(3), pp.205~221 (2002), 대한정신약물학회
  12. 전덕인, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅲ)：치료반응과 내약성", 대한정신약물학회지, 16(4), pp.292~300 (2005), 대한정신약물학회
  13. 김찬형, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅰ)：전반적 평가", 대한정신약물학회지, 16(3), pp.225~233 (2005), 대한정신약물학회
  14. 신영철, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅱ)：약물의 선택", 대한정신약물학회지, 16(4), pp.285~291 (2005), 대한정신약물학회
  15. Jon DI, "Revised Korean Medication Algorithm for Bipolar Disorder", World J Biol Psychiatry, 10(4 Pt 3), pp.846~855 (2009)
  16. Shin YC, "Korean Medication Algorithm for Bipolar Disorder : second revision", Asia Pac Psychiatry, 5, pp.301~308 (2013)
  17. Woo YS, "Korean Medication Algorithm Project for Bipolar Disorder : third revision", Neuropsychiatr Dis Treat, 11, pp.493~506 (2015)
  18. Young Sup Woo, "Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision", Clinical Psychopharmacology and Neuroscience, 16(4), pp.434~448 (2018), 대한정신약물학회[DOI]
  19. Seo JS, "The Korean Medication Algorithm for Depressive Disorder : second revision", J Affect Disord, 167, pp.312~321 (2014)
  20. Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)recommendations for the management of patients with bipolar disorder with mixed presentations", Bipolar Disord, 23, pp.767~788 (2021)
  21. Fountoulakis KN, "A systematic review of the evidence on the treatment of rapid cycling bipolar disorder", Bipolar Disord, 15, pp.115~137 (2013)
  22. Roosen L, "Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review", J Affect Disord, 311, pp.69~77 (2022)
  23. Ogawa Y, "Mood stabilizers and antipsychotics for acute mania : a systematic review and meta-analysis of combination", augmentation therapy versus monotherapy, 2014, pp.28, 989~1003
  24. Grande I, "Pharmacotherapy of acute mania : monotherapy or combination therapy with mood stabilizers and antipsychotics?", CNS Drugs, 29, pp.221~227 (2015)
  25. Sachs GS, "Bipolar mood disorder : practical strategies for acute and maintenance phase treatment", J Clin Psychopharmacol, 16(2 Suppl 1), pp.32~ (1996)[DOI]
  26. Rybakowski JK, "Two generations of mood stabilizers", Int J Neuropsychopharmacol, 10, pp.709~711 (2007)
  27. Bauer MS, "What is a “mood stabilizer”? An evidence-based response", Am J Psychiatry, 161, pp.3~18 (2004)
  28. Goodwin GM, "What is a mood stabilizer?", Psychol Med, 37, pp.609~614 (2007)
  29. Kondo T, "How can we classify"mood stabilizers"with different properties?", Clin Neuropsychopharmacol Ther, 2, pp.12~23 (2011)
  30. Malhi GS, "Defining a mood stabiliser : novel framework for research and clinical practice", BJPsych Open, 4, pp.278~281 (2018)
  31. Jon DI, "The Korean Medication Algorithm Project for Bipolar Disorder(KMAP-BP) : changes in preferred treatment strategies and medications over 16 years and five editions", Bipolar Disord, 22, pp.461~471 (2020)
  32. Vieta E, "Pharmacological management of bipolar depression : acute treatment, maintenance, and prophylaxis", CNS Drugs, 27, pp.515~529 (2013)
  33. Sachs GS, "Effectiveness of adjunctive antidepressant treatment for bipolar depression", N Engl J Med, 356, pp.1711~1722 (2007)
  34. McGirr A, "Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression : a systematic review and meta-analysis of randomised placebo-controlled trials", Lancet Psychiatry, 3, pp.1138~1146 (2016)
  35. Hu Y, "Adjunctive antidepressants for the acute treatment of bipolar depression : a systematic review and meta-analysis", Psychiatry Res, 311, pp.114468~ (2022)
  36. Malhi GS, "The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders", Aust N Z J Psychiatry, 55, pp.7~117 (2021)
  37. Kanba S, "Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders", Psychiatry Clin Neurosci, 67, pp.285~300 (2013)

관련 논문AI추천

Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision송후림, Bo-Hyun Yoon, Duk-In Jon, Inki Sohn, Jeong Seok Seo, Jong Hyun Jeong, Jung Goo Lee, Kyung Joon Min, Moon Doo Kim, Se-Hoon Shim, Won Kim, Won-Myong Bahk, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2018 · 제16권 제4호한국형 양극성 장애 약물치료 알고리듬 2022: 총론김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제2호Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines김문두, 박원명, 심세훈, 전덕인, 정종현, 추일한, Bo-Hyun Yoon, Chan-Mo Yang, Inki Sohn, Jeong Seok Seo, Jung Goo Lee, Myung Hun Jung, Sung-Yong Park, Won Kim, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2023 · 제21권 제1호한국형 양극성 장애 약물치료 알고리듬 2022: 유지치료김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제3호한국형 양극성 장애 약물치료 알고리듬 2022: 조증 삽화김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제2호한국형 양극성 장애 약물치료 알고리듬 2022: 혼재성 양상김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제2호

이 간행물의 다른 논문 (19건)

Clinical Utility of Fluid Biomarker in Depressive DisorderAlessandro Serrettipp. 585-591Efficacy of Olanzapine in Anxiety Dimension of Schizophrenia: A Systematic Review of Randomized Controlled TrialsChiara Amendola, Ilaria Casolaro, Stefano Damiani, Calogero Crapanzanopp. 592-599Botulinum Toxin in Facial Aesthetics Affects the Emotion Process: A Meta-analysis of Randomized Controlled TrialsDelane Viana Gondim, Ana Carolina de Figueiredo Costa, Everton Cavalcante da Silvapp. 600-608Prediction Models for Suicide Attempts among Adolescents Using Machine Learning TechniquesJu-Won Baek, Bung-Nyun Kim, Chan-Mo Yang, Sang Yeol Lee, Jae Seok Limpp. 609-620Cerebellar Gray Matter Volume and its Role in Executive Function, and Attention: Sex Differences by Age in AdolescentsYerin Hyun, Subin Park, Seung-Yup Lee, 김보라, 박민현, 정규인, Bung-Nyun Kim, Bumhee Park, Hayeon Kim, Shin Young Kim, Jiyea Kimpp. 621-634
원문 보기